Cabozantinib
Spécifications
849217-68-1Numéro CAS
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideNom IUPAC
C28H24FN3O5Formule chimique
501.5 g/molMasse molaire
Cabozantinib; 849217-68-1; XL-184; XL 184; BMS-907351; XL-184 free base; BMS 907351; N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; CHEBI:72317; 1C39JW444G; BMS-907351 FREE BASE; XL184 cpd; BMS907351; DTXSID10233968; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-; N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; cabozantinibum; 1,1-CYCLOPROPANEDICARBOXAMIDE, N'-(4-((6,7-DIMETHOXY-4-QUINOLINYL)OXY)PHENYL)-N-(4-FLUOROPHENYL)-; N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N-[4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; RefChem:57604; DTXCID40156459; L01XE26; Cometriq; MFCD20926324; Cabozantinib (XL184, BMS-907351); N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE; Cabozantinib (BMS-907351); Cabozantinib [USAN]; 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; Cabozantinib (USAN); Cabometyx (TN); Cometriq (TN); A1JS8; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; n-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; XL184 free base; Cabozantinib [USAN:INN]; Carbozantinib; UNII-1C39JW444G; Cabozantinib; N'-?[4-?[(6,?7-?Dimethoxy-?4-?quinolinyl)?oxy]?phenyl]?-?N-?(4-?fluorophenyl)?-1,?1-cyclopropanedicarbox?amide; N'-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; BMS 907351; N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; Cabozantinib (Standard); Cabozantinib (XL184); CABOZANTINIB [MI]; Cabozantinib (XL-184); CABOZANTINIB [INN]; CABOZANTINIB [VANDF]; CABOZANTINIB [WHO-DD]; SCHEMBL360795; GTPL5887; orb1305297; CHEMBL2105717; SCHEMBL29351408; EX-A075; GLXC-90066; HMS3654G06; HMS5079K09; XL-184 free base (Cabozantinib); BDBM50021574; EBC-17137; HY-13016R; NSC761068; NSC800066; s1119; AKOS025142112; CCG-264678; CS-0278; DB08875; FD59688; NSC-761068; NSC-800066; SB20062; SDCCGSBI-0646928.P001; XL184,BMS-907351; XL-184 (Cabozantinib,BMS907351); XL-184,Cabozantinib, BMS-907351; NCGC00263164-01; NCGC00263164-12; NCGC00263164-14; NCGC00263164-17; AC-25082; AS-16277; BP-43629; HY-13016; SY097158; XL-184 (Cabozantinib,BMS907351)?; DB-023624; NS00020240; SW218093-3; D10062; AB01565831_02; CABOZANTINIBCT-XL184COMETRIQXL184C3627; Q795057; SR-01000941569; SR-01000941569-1; BRD-K51544265-001-01-8; BRD-K51544265-001-04-2; BRD-K51544265-001-06-7; 1,1-Cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-; 1,1-Cyclopropanedicarboxamide, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-; cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide; cyclopropane-1,1-dicarboxylic acid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4 fluorophenyl)cyclopropane-1,1-dicarboxamide; N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide; N~1~-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl}-N'~1~-(4-fluorophenyl)cyclopropane-1,1-dicarboxamideSynonymes
Produits contenant Cabozantinib
CABOMETYX 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULACABOMETYX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULACABOMETYX 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULACometriq 20mg+80mg capsulas durasCometriq 20mg+80mg capsulas durasCometriq 20mg capsulas durasCABOMETYX 60 MG COMPRIMIDOS RECUBIERTOS CON PELICULACABOMETYX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULACABOMETYX 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULACabozantinibCabozantinibCabozantinib
